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Abstract
Scanty data are available on the incidence (i.e., the absolute risk) of second cancers of the head
and neck (HN) and its pattern with age. We investigated this issue using data from a multicentric
study of 13 population-based cancer registries from Europe, Canada, Australia and Singapore for
the years 1943-2000. A total of 99,257 patients had a first primary HN cancer (15,985 tongue,
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22,378 mouth, 20,758 pharyngeal, and 40,190 laryngeal cancer), contributing to 489,855 person-
years of follow-up. 1294 of the patients (1.3%) were diagnosed with second HN cancers (342
tongue, 345 mouth, 418 pharynx, and 189 larynx). Male incidence rates of first HN cancer steeply
increased from 0.68/100,000 at age 30-34 to 46.2/100,000 at age 70-74, and leveled off at higher
age; female incidence increased from 0.50/100,000 at age 30-34 to 16.5/100,000 at age 80-84.
However, age-specific incidence of second HN cancers after a first HN cancer in men was around
200-300/100,000 between age 40-44 and age 70-74, and tended to decline at subsequent ages
(150/100,000 at age 80-84); in women, incidence of second HN cancers was around
200-300/100,000 between age 45-49 and 80-84. The patterns of age-specific incidence were
consistent for different subsites of second HN cancer and sexes; moreover, they were similar for
age-specific incidence of first primary HN cancer in patients who subsequently developed a
second HN cancer. The incidence of second HN cancers does not increase with age, but remains
constant, or if anything, decreases with advancing age.
Impact statement—While the incidence of first primary cancers of the head and neck increases
with advancing age that of second primary cancers is stable between age 40 and 70 and, if
anything, declines thereafter.
Keywords
second neoplasms; head and neck cancer; incidence; age
INTRODUCTION
Patients who had a cancer in one of the organs of the head and neck (HN) have a substantial
excess risk of a second primary cancer in the same or another HN organ, and this is a major
reason for their poor prognosis 1-3. Moreover, it has been shown that relative risks (RR) of
second HN cancers are higher at younger age, and decline with advancing age 4, 5.
Population-based information on the incidence of second cancers of the HN, and on its
relation with age are available only from a series of about 3,000 cancers of the oral cavity
and pharynx registered between 1974 and 2003 in the Swiss Cantons of Vaud and
Neuchatel, including 233 second cancers 4. The incidence of second oral and pharyngeal
cancers showed no increase with age, and indeed declined from 30.3/1000 at age 40-49 to
12.5/1000 at age 70-79 years, in sharp contrast with the incidence of the first primary
cancer, which increased 20-fold between age 30-39 and 70-89 4. Thus, those data suggested
that the incidence of second primary cancers of the HN follows the same pattern observed
for breast and a few other neoplasms, indicating no increasing incidence of second
neoplasms with age 5-13.
In order to further investigate the age-relation of the incidence of second HN cancers,
overall and within subsites, we analyzed data from a multicentric study including 13
population-based cancer registries from Europe, Canada, Australia and Singapore. A
previous report on the same dataset analyzed the standardized incidence rates (SIR) of
second HN cancers, and their relation with age at and time since diagnosis of the first HN
cancer, as well as the cumulative risk of second HN cancers 14.
MATERIALS AND METHODS
Data were derived from an international multicenter study of cancer registries that have been
in operation for at least 25 years to conduct a systematic analysis of second primary cancers
14, 15. Briefly, the registries include New South Wales in Australia, British Columbia,
Manitoba and Saskatchewan in Canada, Denmark, Finland, Iceland, Norway, Scotland,
Singapore, Slovenia, Sweden, and Zaragoza in Spain. These registries had cancer data
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covering different time periods within 1943 2000. A high degree of completeness of
ascertainment by the registry is suggested by an appropriate level of microscopically
verified cases, a low proportion of cases registered from death certificates only, and their
consistent inclusion in the “Cancer Incidence in Five Continents” series 16.
Data were provided from each cancer registry on all first primary cancers, including age and
sex of the patient, diagnosis and date of the first primary, follow-up for mortality and
diagnosis and date of the second primary, if any. In this study, registries used different
cancer codes, which were systematically converted into those of the International
Classification of Disease, Ninth Revision (ICD-9).
Here, we analyzed the occurrence of second HN cancers in patients who survived from first
primary HN cancer (ICD-9 codes: tongue: 141; mouth: 143 145; oropharynx: 146;
hypopharynx: 148; pharynx unspecified: 149 and larynx: 161), who have already been
included in a previous report 14. Lip (ICD-9: 140), salivary glands (ICD-9: 142) and
nasopharyngeal cancer (ICD-9: 147) were not included in the analysis.
Coding of multiple primaries in the cancer registries has followed a common set of rules
proposed by the International Association of Cancer Registries and the International Agency
for Research on Cancer 17. According to the rules, a primary cancer is one that originates in
a primary site or tissue and is thus neither an extension, nor a recurrence, nor a metastasis.
Second HN cancers from the same site (defined as tongue, other parts of the mouth,
oropharynx, hypopharynx, pharynx unspecified, and larynx) as the first primary cancer were
excluded from registration in most cancer registration areas, and are therefore not considered
in the present report.
All cases of first primary HN cancers were followed up for second HN cancers from the date
of HN cancer diagnosis (1943–2000) to the date of second HN cancers (1943–2000), the
date of death or end of follow-up (1992–2000), depending on the coverage of each registry
when the study closed.
Expected numbers of second HN cancers were calculated from the accumulated person-
years and the age-, sex-, calendar period-specific first primary HN cancer incidence rates in
each of the cancer registries 18. By comparing the observed and expected number of second
HN cancers, we computed the SIR of HN cancer, and the corresponding 95% confidence
intervals (CIs), based on the Poisson distribution.
We computed age-specific incidence rates/100,000 of first HN cancer in the populations
covered by the cancer registries, and those of second HN cancer in the cohort of patients
with a first HN cancer. For Denmark, Norway, Scotland, Slovenia, Sweden, Spain and
Manitoba, the registries provided the population covered by sex, age and calendar year. For
other registries, population data were derived from the “Cancer Incidence in Five
Continents” volumes 16.
RESULTS
A total of 99,257 patients (74,988 men; 24,269 women; median age 63) had a first primary
HN cancer (15,985 tongue, 22,378 mouth, 20,758 pharyngeal, and 40,190 laryngeal cancer)
who contributed 489,855 person-years of follow-up (mean follow-up time: 4.9 years).
During the follow-up period, 1294 of these patients (1.3%) were diagnosed with second HN
cancers at a different site (342 of the tongue, 345 of the mouth, 418 of the pharynx, and 189
of the larynx), versus 115.75 expected, corresponding to a SIR of 11.2 (95% CI 10.6-11.8)
(Table 1). The SIR was 9.5 in men (based on 995 cases), and 28.3 in women (based on 299
cases). The SIR was 16.4 under age 50, and decreased to 8.8 at age 70 or more. A similar
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pattern was observed in both sexes, although the decrease in the SIR with increasing age at
diagnosis was smaller in women (SIR=36.8 at age <50 and 24.5 at age ≥70) than in men
(SIR=14.6 at age <50 and 6.2 at age ≥70). With reference to subsite at first HN cancer, the
SIRs were 16.7 when the site of the first cancer was the tongue, 14.1 when it was the mouth,
14.0 when it was the pharynx, and 7.1 when it was the larynx. Corresponding figures were
13.2, 11.3, 12.0 and 6.7 in men, and 36.6, 32.4, 31.8 and 13.8 in women. Considering
subsites at second HN cancer, the SIRs were 16.0 when the site of the second cancer was the
tongue, 12.5 when it was the mouth, 11.7 when it was the pharynx, and 6.1 when it was the
larynx. Corresponding figures were 12.6, 10.1, 10.6 and 5.6 in men, and 40.9, 30.9, 24.9 and
12.9 in women.
Figure 1 shows the age-specific incidence of first HN cancer (overall and by subsite) in men
and women separately. In men, incidence rates steeply increased from 0.68/100,000 at age
30-34 to 46.2/100,000 at age 70-74, and leveled off at higher age; in women, incidence
increased from 0.50/100,000 at age 30-34 to 16.5/100,000 at age 80-84. Similar patterns
were observed for various subsites of HN.
The age curve was totally different for second HN cancers, as shown in Figure 2. The age-
specific incidence of second HN cancers after a first HN cancer in men was around
200-300/100,000 between age 40-44 and age 70-74, and tended to decline at subsequent
ages (150/100,000 at age 80-84). Though the patterns were less stable in women due to the
lower number of female HN cancer patients, the incidence of second HN cancers was
similar to that in men around 200-300/100,000 between age 45-49 and 80-84. The patterns
of age-specific incidence were consistent for different subsites of second HN cancer, both in
men and in women.
Analyses of incidence of second HN cancers by subsite of first HN cancer showed similar
age patterns – although less stable – to those observed in the overall analysis (Figure 3).
DISCUSSION
Our data confirm the existence of a substantial excess risk of HN cancer in patients who had
a previous HN cancer as compared to the general population. At every age, incidence rate of
second HN cancers was greater than the rate of first primary cancers, with particularly high
relative risk at younger ages. This is due to the fact that – as observed for breast cancer and
for a few other cancer sites for which it was possible to analyze the incidence of second
primary tumors 5-13 – the incidence of second HN cancers does not increase with age, but
remains constant, or if anything, decreases with advancing age. The higher relative risk of
HN cancers in younger observed in this as in a few other studies 4, 5, 19, well reflects the
age-specific incidence curves of second HN cancers. Likewise, the incidence of primary HN
cancers in patients who eventually developed a second HN cancer does not rise with a power
of age. Rates for all HN sites at age 50 to 75 ranged around 0.40-0.50/100,000 in men and
around 0.1 in women (data not shown in Figure).
Consistent age-specific incidence patterns were observed for various organs within the HN
(i.e., tongue, other parts of the mouth, pharynx and larynx), as well as HN cancers after a
first cancer at the same organs, although the incidence of second HN cancer was generally
lower when the first HN cancer originated in the larynx.
The observed age-specific incidence patterns were also consistent in men and women,
although in women the rates were less stable, due to lower number of female patients.
Interestingly, we observed that, while the incidence of first HN cancer is lower in women
than in men, the incidence of second cancer is similar in the two sexes, and consequently the
SIRs of second cancer are higher in women than in men 19, 20. This has not been reported
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previously, probably because the small sample size of previous studies has precluded
separate analyses for women.
The present findings confirm the age- specific incidence patterns of second primary cancers
reported in a previous analysis on oral and pharyngeal cancer in two Swiss cancer registries
4. The estimates of the absolute, as well as the relative, risk of second HN cancers in our
data are, however, lower than those reported in those cancer registries. This can be due to
various factors, including the higher baseline incidence of oral and pharyngeal cancers in
Switzerland as compared to most countries included in this pooled analysis 16 and the
different registration and exclusion criteria of second tumors in those Swiss registries, as
compared to most of those included in our analyses. The Swiss registries have an active
follow-up of cancer, in particular HN, patients, as also indicated by the high proportion of
patients with a second primary cancer of the oral cavity and pharynx (7.5%) observed in that
cohort, as compared to that reported in our as well as in other studies 19, 21. Our SIR
estimates are, however, comparable with those observed in a nationwide database from
Sweden 21, and higher that those from a few other studies from northern Europe 19, 22.
The interpretation of the age-specific incidence curves for second HN cancers is not simple.
Subjects with a primary cancer of the HN differ from the general population in several
aspects, which can affect their risk of a new primary tumor. They constitute a group of
susceptible subjects, probably characterized by a high genetic predisposition. Moreover, the
exposure to the agents which caused the primary tumors may also have triggered the
development of multiple primary cancers at other HN sites, originated by the same field as
proposed within the “field cancerization” theory 23, 24 or originated from multiple
independent lesions 25. The treatments for their first cancer may also affect their risk of
developing a subsequent primary cancer.
The power relation with age of the incidence of first primary HN cancer has been interpreted
within the multistage model of carcinogenesis, as an indication that tumors arise from the
accumulation of several essentially random genetic changes 26. On the other hand, the
constant age patterns of second HN cancers are not compatible with the occurrence of a
number (5 to 8) of subsequent mutational events or clones of cells 27, 28, but indicate that
this population of susceptible individuals may need a single additional mutational event to
develop a second cancer 29, 30. This is also supported by the similar age pattern for primary
HN cancers in patients who had second HN cancers, observed also for other neoplasms 5, 8,
13.
The tendency for a decline in the incidence of second primary neoplasms of the HN may be
partly due to selective stopping of risk factors modifiable in middle and elderly age, i.e.
smoking and alcohol drinking in (elderly) patients with a first diagnosis of HN cancer, with
the consequent fall in their risk of HN cancer 31. This can, however, be caused by the
progressive elimination of predisposed (very high risk) individuals at young ages, as
suggested also for breast cancer 8, 10, 29, 30, together with some possible under-reporting at
elderly ages, which, however, is unlikely to explain a decline in rates starting at age 55. A
fall in rates in the elderly may also be due to some reduction in the ability to respond to
promoters, as indicated by animal experiments on mice given initiators and promoters at
different times in their life 32, 33.
Increased surveillance of patients who had a first primary HN cancer and some
misclassification – due to difficulties to distinguish second primary cancers from recurrence
of first tumors or metastases – may have affected our rates estimates. We have adopted strict
rules to exclude recurrences of first primaries. This may have led to underestimation of the
real cancer rates, but cannot account for the observed age-specific incidence curves. The
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relatively long follow-up and, mostly, the large number of patients are among the strengths
of this study, which allowed us to provide estimates of age-specific incidence rates of
second HN cancers, not only overall, but also by sex and subsites.
In terms of individual risk assessment and clinical implications, these results indicate that
young HN cancer patients, although rare, are at particularly high risk of developing another
primary cancer in the HN. The rates of second HN cancers of the order of 150 to
250/100,000 in the fifth decade of age are indeed comparable or larger than the rates of all
cancers in the general population at age 40 to 49 34.
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Figure 1.
Age-specific incidence rate of first cancers of the head and neck in the general population, in
74,988 male (a) and 24,269 female (b) cases.
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Figure 2.
Age-specific incidence rate of second cancers of the head and neck in 995 men (a) and 299
women (b) who had a first cancer of the head and neck.
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Figure 3.
Age-specific incidence rate of second cancers of the head and neck in patients who had a
first cancer of the tongue (a), mouth (b), pharynx (c) and larynx (d).
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